V Craig Jordan

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. pmc The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities
    V Craig Jordan
    Lomhardi Comprehensive Cancer Center, Georgetown University, Washington, BC 20057, USA
    Breast 20:S1-11. 2011
  2. pmc The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice
    Philipp Y Maximov
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Curr Clin Pharmacol 8:135-55. 2013
  3. pmc Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis
    V Craig Jordan
    Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 4:633-7. 2011
  4. pmc Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    Eur J Cancer 50:457-68. 2014
  5. doi request reprint Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story
    Russell E McDaniel
    Department of Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA
    Vitam Horm 93:1-49. 2013
  6. pmc Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality
    Ifeyinwa Obiorah
    Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA
    Menopause 20:372-82. 2013
  7. pmc Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Washington, DC 20057, USA
    Eur J Cancer 48:3488-98. 2012
  8. pmc Progress in endocrine approaches to the treatment and prevention of breast cancer
    Ifeyinwa Obiorah
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, United States
    Maturitas 70:315-21. 2011
  9. pmc Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer
    Ifeyinwa Obiorah
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia I O, S S, V C J and Institute of Chemistry, Romanian Academy, Timisoara, Romania R C
    Mol Pharmacol 85:789-99. 2014
  10. pmc c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    Cancer Res 73:4510-20. 2013

Collaborators

  • Zhang Zhi Hu
  • Anton Wellstein
  • Obi L Griffith
  • Seung Sang Ko
  • Ping Fan
  • Russell E McDaniel
  • Ifeyinwa Obiorah
  • Philipp Y Maximov
  • Elizabeth E Sweeney
  • Karen Creswell
  • Xiaojun Zou
  • Fadeke A Agboke
  • Cynthia B Myers
  • Surojeet Sengupta
  • Ramona Curpan
  • Ramona F Curpan
  • Daphne J Fernandes
  • Pavana Anur
  • John A Katzenellenbogen
  • Theresa M Lee
  • Sung Hoon Kim
  • Joe W Gray
  • Helen R Kim
  • Bassem Haddad
  • Dionyssia Clagett

Detail Information

Publications14

  1. pmc The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities
    V Craig Jordan
    Lomhardi Comprehensive Cancer Center, Georgetown University, Washington, BC 20057, USA
    Breast 20:S1-11. 2011
    ....
  2. pmc The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice
    Philipp Y Maximov
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Curr Clin Pharmacol 8:135-55. 2013
    ..In this article, we describe the discovery and development of the group of medicines called SERMs. The newer SERMs in late development: ospemifene, lasofoxifene, bazedoxifene, are arzoxifene are described in detail...
  3. pmc Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis
    V Craig Jordan
    Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 4:633-7. 2011
    ..Cell populations emerge with a vulnerability, as estrogen is no longer a survival signal but is an apoptotic trigger. The antitumor effect of ERT in estrogen-deprived postmenopausal women is consistent with laboratory models...
  4. pmc Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    Eur J Cancer 50:457-68. 2014
    ..To mimic the clinical administration of c-Src inhibitors, we treated cells with either E2, a c-Src inhibitor PP2, or the combination for 8 weeks to further explore the apoptotic potential of the c-Src inhibitor and E2 on MCF-7:5C cells...
  5. doi request reprint Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story
    Russell E McDaniel
    Department of Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA
    Vitam Horm 93:1-49. 2013
    ....
  6. pmc Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality
    Ifeyinwa Obiorah
    Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA
    Menopause 20:372-82. 2013
    ..These nascent tumors are now vulnerable to estrogen-induced apoptosis. ..
  7. pmc Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Washington, DC 20057, USA
    Eur J Cancer 48:3488-98. 2012
    ..A specific c-Src inhibitor, 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazolo[3,4-d]pyrinidine (PP2), was utilised to block c-Src activity to identify targeted vulnerabilities affected by ER and HER2 in a panel of breast cancer cell lines...
  8. pmc Progress in endocrine approaches to the treatment and prevention of breast cancer
    Ifeyinwa Obiorah
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, United States
    Maturitas 70:315-21. 2011
    ..This review outlines the current strategies employed in the use of endocrine therapy in the management and prevention of breast cancer...
  9. pmc Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer
    Ifeyinwa Obiorah
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia I O, S S, V C J and Institute of Chemistry, Romanian Academy, Timisoara, Romania R C
    Mol Pharmacol 85:789-99. 2014
    ..The fully activated ER complex with helix 12 sealing the LBD is suggested to be the appropriate trigger to initiate rapid estrogen-induced apoptosis. ..
  10. pmc c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    Cancer Res 73:4510-20. 2013
    ..This work offers a mechanistic rationale for a new approach in the treatment of endocrine-resistant breast cancer...
  11. pmc Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells
    Philipp Y Maximov
    Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Research Building, Suite E501, Washington, D C 20057, United States
    J Med Chem 57:4569-83. 2014
    ..Molecular modeling demonstrated that some compounds would each create a best fit with a novel agonist conformation of the ER. The results demonstrate modulation by the ER complex of cell replication or gene transcription in cancer. ..
  12. doi request reprint Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells
    Elizabeth E Sweeney
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Int J Oncol 44:1529-38. 2014
    ..Additionally, increased insulin-like growth factor receptor β (IGF-1Rβ) confers a mechanism of growth and anti-apoptotic advantage in MCF-7:2A cells...
  13. pmc Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells
    Zhang Zhi Hu
    Lombardi Cancer Center, Georgetown University, Washington, DC, United States of America
    PLoS ONE 6:e20410. 2011
    ..Paradoxically, in breast cancer cells that have been chronically deprived of estrogen stimulation, re-introduction of the hormone can induce apoptosis...
  14. pmc Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene
    Seung Sang Ko
    Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Department of Oncology, 3970 Reservoir Rd N W, Washington, DC 20057, USA
    Expert Opin Pharmacother 12:657-74. 2011
    ..The SERM, raloxifene, is used for the prevention and for the treatment of postmenopausal osteoporosis and reducing the risk of invasive breast cancer in postmenopausal women...